Here is IP Think Tank’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://thinkipstrategy.com/subscribe/

Cozaar (Losartan) – Brazil/India/EU: Brazilian ambassador to WTO condemns EU for seizing shipment of generic drugs bound for Brazil; Dr Reddy’s takes prudent option, asks for return of seized consignment (IP tango) (Spicy IP) (GenericsWeb)

US: Senate bill would prevent reverse pharma payments – Preserve Access to Affordable Generics Act (S 396) (IP Watchdog) (Patent Baristas) (Hal Wegner)

Should authorised generics be abolished? (IP Think Tank)

Proponents explore designs for prizes to aid neglected disease research (Intellectual Property Watch)

Why have the fine and speciality chemical sectors been moving from developed countries? (Profitability through Simplicity)

Patent World SPC round-up ‘Prolonging Patent Protection’ by Marjan Noor (SPC Blog)

EU: Commission’s view on paediatric extensions (The SPC Blog)

EU: Suing, not suing both attract the Commission’s attention – EU pharma inquiry (PatLit)

EU: Life Science marks held confusingly similar: Bayern Innovativ – Bayerische Gesellschaft für Innovation und Wissenstransfer mbH, v Office for Harmonisation in the Internal Market, Life Sciences Partners Perstock NV (Class 46)

US: Senate bill would prevent reverse pharma payments – Preserve Access to Affordable Generics Act (S 396) (IP Watchdog) (Patent Baristas) (Hal Wegner)

US: Bill introduced to prohibit marketing of authorised generic drugs (Patent Baristas)

US: More § 154(b)(4)(A) patent term adjustment actions filed against Director Jon Dudas: latest complaints filed by Bayer Bioscience and Max-Planck-Gesellschaft zur Foderung der Wissnschaften, Syntonix, General Hospital Corporation of Boston (Patent Docs)

US: Myriad Genetics files amicus in support of Prometheus: Prometheus v Mayo (Holman’s Biotech IP Blog)

US: FDA approves first biological product derived from genetically engineered animals (FDA Law Blog) (Law360)

US: Will Chief Justice Roberts recuse in Wyeth v Levine? (PharmaLittle)

US: PerkinElmer sues Interna to invalidate down syndrome test patent (Law360)

US: Monsanto files patent suit against Michigan farmers Earl and Richard Schroeder accusing them of planting pesticide-resistant seeds without paying proper royalties (Law360)

US: Case to watch: preclusive effect of prior claim construction: Shire v Sandoz (Patently-O)

AndroGel (Testosterone) – US: Federal Trade Commission continues campaign against reverse payments, filing complaint against Solvay and generics makers Watson, Par and Paddock (Managing Intellectual Property) (IP Frontline)

Boniva (Ibandronic acid) – US: Roche removes patent from Boniva litigation (Patent Docs)

Claratin (Loratadine) – US: GeoPharma and Dr Reddy’s resolve patent litigation related to Claratin (Patent Docs)

Cozaar (Losartan) – Brazil/India/EU: Brazilian ambassador to WTO condemns EU for seizing shipment of generic drugs bound for Brazil; Dr Reddy’s takes prudent option, asks for return of seized consignment (IP tango) (Spicy IP) (GenericsWeb)

Cubicin (Daptomycin) – US: Cubist plans to commence patent infringement litigation against Teva in response to ANDA filing (GenericsWeb) (Philip Brooks’ Patent Infringement Updates)

Januvia (Sitagliptine) – Netherlands: Zero-term SPC in Sitagliptine application (SPC Blog)

Nexavar (Sorafenib) – India: Bayer sues Indian government to retain monopoly right (GenericsWeb)

Paxil (Paroxetine) – US: Par Pharmaceutical announces outcome of the litigation with Pentech Pharmaceuticals (SmartBrief)

Valcyte (Valanciclovir) – India: Patent Office rejects Valganciclovir pre-grant opposition (Patent Circle) (Patent Circle) (Patent Circle)